Illumina (NASDAQ:ILMN) Stock Rating Upgraded by BidaskClub

BidaskClub upgraded shares of Illumina (NASDAQ:ILMN) from a hold rating to a buy rating in a research note issued to investors on Wednesday morning, BidAskClub reports.

Other analysts also recently issued research reports about the stock. UBS Group increased their price objective on shares of Illumina from $350.00 to $355.00 and gave the company a buy rating in a report on Tuesday, July 30th. Cowen dropped their target price on shares of Illumina from $380.00 to $320.00 and set an outperform rating on the stock in a report on Friday, July 12th. Bank of America cut shares of Illumina from a buy rating to an underperform rating and set a $310.00 target price on the stock. in a report on Friday, July 12th. Argus increased their target price on shares of Illumina from $300.00 to $340.00 and gave the stock a buy rating in a report on Wednesday, September 25th. Finally, ValuEngine raised shares of Illumina from a hold rating to a buy rating in a report on Thursday, September 12th. One analyst has rated the stock with a sell rating, three have issued a hold rating and twelve have issued a buy rating to the company. Illumina currently has an average rating of Buy and a consensus target price of $330.92.

Shares of NASDAQ ILMN traded up $2.22 during trading hours on Wednesday, reaching $311.89. The stock had a trading volume of 236,661 shares, compared to its average volume of 868,880. The company has a current ratio of 6.79, a quick ratio of 6.10 and a debt-to-equity ratio of 0.42. The firm has a market cap of $45.62 billion, a price-to-earnings ratio of 54.53, a P/E/G ratio of 3.09 and a beta of 1.07. The business’s fifty day moving average price is $293.87 and its two-hundred day moving average price is $312.98. Illumina has a 52-week low of $263.30 and a 52-week high of $380.76.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Monday, July 29th. The life sciences company reported $1.35 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.32 by $0.03. The firm had revenue of $838.00 million during the quarter, compared to analyst estimates of $835.12 million. Illumina had a return on equity of 21.73% and a net margin of 27.56%. Illumina’s quarterly revenue was up 1.0% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.43 earnings per share. Equities research analysts anticipate that Illumina will post 6.04 earnings per share for the current fiscal year.

In other news, Director Jay T. Flatley sold 3,300 shares of the firm’s stock in a transaction dated Wednesday, July 24th. The shares were sold at an average price of $304.00, for a total transaction of $1,003,200.00. Following the completion of the transaction, the director now owns 269,316 shares in the company, valued at approximately $81,872,064. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, SVP Mostafa Ronaghi sold 10,000 shares of the firm’s stock in a transaction dated Thursday, August 15th. The shares were sold at an average price of $285.52, for a total transaction of $2,855,200.00. Following the transaction, the senior vice president now owns 86,585 shares of the company’s stock, valued at approximately $24,721,749.20. The disclosure for this sale can be found here. In the last ninety days, insiders sold 37,099 shares of company stock worth $10,877,060. Corporate insiders own 0.38% of the company’s stock.

Several large investors have recently bought and sold shares of the company. Broderick Brian C boosted its position in shares of Illumina by 0.3% during the 2nd quarter. Broderick Brian C now owns 13,240 shares of the life sciences company’s stock valued at $4,874,000 after purchasing an additional 36 shares in the last quarter. Foresight Wealth Management LLC boosted its position in shares of Illumina by 4.2% during the 2nd quarter. Foresight Wealth Management LLC now owns 972 shares of the life sciences company’s stock valued at $358,000 after purchasing an additional 39 shares in the last quarter. Bbva USA Bancshares Inc. boosted its position in shares of Illumina by 2.0% during the 2nd quarter. Bbva USA Bancshares Inc. now owns 2,020 shares of the life sciences company’s stock valued at $743,000 after purchasing an additional 40 shares in the last quarter. Greenleaf Trust boosted its position in shares of Illumina by 0.6% during the 2nd quarter. Greenleaf Trust now owns 6,691 shares of the life sciences company’s stock valued at $2,463,000 after purchasing an additional 42 shares in the last quarter. Finally, Bath Savings Trust Co boosted its position in shares of Illumina by 4.0% during the 3rd quarter. Bath Savings Trust Co now owns 1,105 shares of the life sciences company’s stock valued at $336,000 after purchasing an additional 43 shares in the last quarter. Institutional investors own 90.96% of the company’s stock.

Illumina Company Profile

Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array.

Featured Article: Are we seeing the beginning of a new bubble?

Analyst Recommendations for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.